S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61

Aerie Pharmaceuticals Stock Forecast, Price & News

-0.11 (-1.13%)
(As of 12/8/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.93 million shs
Average Volume
672,822 shs
Market Capitalization
$457.00 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Aerie Pharmaceuticals logo

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$83.14 million
Book Value
($1.54) per share


Net Income
$-183.10 million
Net Margins
Pretax Margin




Free Float
Market Cap
$457.00 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.79 out of 5 stars

Medical Sector

852nd out of 1,394 stocks

Biological Products, Except Diagnostic Industry

131st out of 202 stocks

Analyst Opinion: 3.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

Is Aerie Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aerie Pharmaceuticals stock.
View analyst ratings for Aerie Pharmaceuticals
or view top-rated stocks.

How has Aerie Pharmaceuticals' stock price been impacted by COVID-19?

Aerie Pharmaceuticals' stock was trading at $14.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AERI shares have decreased by 33.7% and is now trading at $9.65.
View which stocks have been most impacted by COVID-19

Are investors shorting Aerie Pharmaceuticals?

Aerie Pharmaceuticals saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 4,270,000 shares, a decrease of 26.4% from the October 31st total of 5,800,000 shares. Based on an average daily trading volume, of 812,900 shares, the short-interest ratio is presently 5.3 days. Approximately 9.4% of the company's shares are sold short.
View Aerie Pharmaceuticals' Short Interest

When is Aerie Pharmaceuticals' next earnings date?

Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Aerie Pharmaceuticals

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by $0.10. The company had revenue of $29.31 million for the quarter, compared to analyst estimates of $29.13 million. Aerie Pharmaceuticals had a negative trailing twelve-month return on equity of 1,531.00% and a negative net margin of 159.85%. During the same period in the prior year, the firm earned ($0.65) EPS.
View Aerie Pharmaceuticals' earnings history

What price target have analysts set for AERI?

4 analysts have issued twelve-month price objectives for Aerie Pharmaceuticals' shares. Their forecasts range from $15.65 to $29.00. On average, they expect Aerie Pharmaceuticals' stock price to reach $23.66 in the next twelve months. This suggests a possible upside of 145.2% from the stock's current price.
View analysts' price targets for Aerie Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the following people:
  • Thomas A. Mitro, President & Chief Operating Officer
  • Casey C. Kopczynski, Chief Scientific Officer
  • Richard Lewis, Chief Medical Officer
  • Luis G. Vargas, Medical Director
  • David A. Hollander, Chief Research & Development Officer

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include (CGC), Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Who are Aerie Pharmaceuticals' major shareholders?

Aerie Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include William Blair Investment Management LLC (6.08%), Granahan Investment Management Inc. MA (2.94%), Schroder Investment Management Group (2.81%), Citigroup Inc. (2.65%), Rice Hall James & Associates LLC (2.61%) and Pinnacle Associates Ltd. (1.46%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski and Gerald D Cagle.
View institutional ownership trends for Aerie Pharmaceuticals

Which major investors are selling Aerie Pharmaceuticals stock?

AERI stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Integral Health Asset Management LLC, Geode Capital Management LLC, Millennium Management LLC, Schroder Investment Management Group, Voloridge Investment Management LLC, Two Sigma Advisers LP, and Renaissance Technologies LLC.
View insider buying and selling activity for Aerie Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Aerie Pharmaceuticals stock?

AERI stock was bought by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Granite Investment Partners LLC, Tudor Investment Corp Et Al, Jacob Asset Management of New York LLC, Citadel Advisors LLC, Martingale Asset Management L P, Endurance Wealth Management Inc., and Thompson Investment Management Inc..
View insider buying and selling activity for Aerie Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $9.65.

How much money does Aerie Pharmaceuticals make?

Aerie Pharmaceuticals has a market capitalization of $457.00 million and generates $83.14 million in revenue each year. The company earns $-183.10 million in net income (profit) each year or ($3.61) on an earnings per share basis.

How many employees does Aerie Pharmaceuticals have?

Aerie Pharmaceuticals employs 365 workers across the globe.

What is Aerie Pharmaceuticals' official website?

The official website for Aerie Pharmaceuticals is www.aeriepharma.com.

Where are Aerie Pharmaceuticals' headquarters?

Aerie Pharmaceuticals is headquartered at 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at (919) 237-5300, via email at [email protected], or via fax at 949-526-8787.

This page was last updated on 12/9/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.